Sionna Therapeutics, Inc. (SION) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 7.18 |
| Open | 7.14 |
| Day High | 7.14 |
| Day Low | 5.91 |
| 52-Week High | 54.97 |
| 52-Week Low | 4.01 |
| Volume | 3.7M |
| Average Volume | 2.05M |
| Market Cap | 269.1M |
| PE | -2.73 |
| EPS | -2.18 |
| Moving Average 50 Days | 23.27 |
| Moving Average 200 Days | 35.59 |
| Change | -1.22 |
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicin
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicin
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicin